Vyant Bio, Inc. Quarterly report pursuant to sections 13 or 15(d)

Notes Payable and Lines of Credit (Tables)

9 Months Ended

Sep. 30, 2013

Below is a summary of our short-term and long-term debt obligations as of September 30, 2013 and December 31, 2012:


	September 30, 2013		December 31, 2012
December 2011 Financing Transaction	$	—	$	4,000,000
Secured Note Payable, short-term		43,622		79,867
Unamortized debt discount		—		(243,300	)

Notes Payable, Current Portion	$	43,622	$	3,836,567

Lines of Credit, Current Portion	$	6,000,000	$	3,000,000
Unamortized Debt Discount		—		(128,800	)

Lines of Credit, Current Portion	$	6,000,000	$	2,871,200

December 2011 Financing Transaction	$	—	$	2,000,000
2012 Convertible Debt Financing Transaction		—		3,000,000
December 2012 Bridge Financing Transaction		—		1,000,000
Other Note Payable		—		100,000
Secured Note Payable		—		22,298
Unamortized debt discount		—		(3,681,615	)

Notes Payable, Long-Term	$	—	$	2,440,683

Lines of Credit, Long-Term	$	—	$	6,000,000

On April 10, 2013, we completed our IPO and converted the following indebtedness into shares of common stock at the IPO price of $10.00 per share:


	Converted Amount		Common Shares
December 2011 Financing Transaction	$	4,500,000		450,000
2012 Convertible Debt Financing Transaction		3,000,000		300,000
December 2012 Bridge Financing Transaction		1,000,000		100,000
Business Lines of Credit (DAM)		1,000,000		100,000
Other Note Payable and accrued interest		134,300		13,430

	$	9,634,300		963,430